WIXLIB

CV: Robert A. Stern, sent2017-Present2018-20192019-Present-Page 6CONSULTATION, BOARD MEMBERSHIPS, AND INDUSTRY ACTIVITIES:Cato Research, Ltd. (Clinical Trials Design and Implementation) Durham, NC“HIV: Neuropsychiatric and Psychoimmune Relationships” (Dwight Evans, PI; R01Grant), Department of Psychiatry, University of Pennsylvania“A Telephone Intervention for Dementia Caregivers” (Geoffrey Tremont, PI; R21 Grant),Rhode Island Hospital/Brown Medical School“A Longitudinal Study of Hazardous Drivers with Dementia” (Brian Ott, PI; R01 Grant),Memorial Hospital of Rhode Island/Brown Medical SchoolOutcome Science (for Forest Laboratories), Cambridge, MAElan Pharmaceuticals, San Francisco, CANeuronix, Yokneam, IsraelEli Lilly (Expert Advisor), Indianapolis, INJanssen Alzheimer Immunotherapy, San Francisco, CAAthena Diagnostics (Quest), Worcester, MAJanssen Research & Development, Titusville, NJAmarantus Bioscience, Member, Alzheimer’s Disease Advisory BoardAdelphi Values; Expert Panel Member, C-Path's PRO ConsortiumAvanir Pharmaceuticals, Member, TBI Advisory BoardBiogen, Member, Alzheimer’s Medical Scientific Advisory CommitteeBiogen, Member, Alzheimer’s Disease Patient Journey Working Group (Co-Chair, May2017 Meeting)Biogen, Member, Alzheimer’s Disease Cognitive Endpoints Project CommitteeEli Lilly, Member, Executive Committee for AZD3293 Alzheimer’s Disease StudiesNCAA Student-Athlete Concussion Injury Litigation, Court-Appointed Member, MedicalScientific CommitteeKing-Devick Test, Inc., Member, Board of DirectorsBiogen, Member, ADvance Medical Education International Working GroupPowering Precision Health (PPH; a non-profit 501(c)(6) organization), Member,Advisory BoardLICENSES AND CERTIFICATION:1990-1994Licensed Psychologist, North Carolina License # 15601993-2008Licensed Psychologist, Rhode Island # 4911992-PresentRegistrant, National Register of Health Service Providers in Psychology1997-PresentLicensed Psychologist HSP, Massachusetts # 7238TEACHING EXPERIENCE AND 9931990-19931990-19931990-1993Member, Clinical Psychology Training Program, UNC School of MedicineRegular Lecturer for Internship Seminar Series, UNC School of MedicineMentor and Supervisor, Neuropsychology Clinical Post-doctoral Fellows and Predoctoral Interns, Dept. of Psychiatry, UNC School of MedicineMentor for Psychiatry Research Fellows, Research Fellowship Training Program, UNCSchool of MedicineMember, Training Faculty Institutional National Research Service Award FellowshipTraining Program; Brain and Development Research Center, UNC School of MedicineCo-director, Neuropsychiatry Seminar Series, UNC School of MedicineRegular lecturer, Consult/Liaison Seminar Series, UNC Psychiatry Residency TrainingProgram, UNC School of Medicine

CV: Robert A. Stern, -Present2006-2008-Page 7Co-director, “Brain-Behavior Relationships”, 3rd year medical school course; UNCSchool of MedicineRegular Lecturer, 1st year Neurobiology Course, UNC School of MedicineRegular Lecturer, “Adult Language Disorders” Course, Division of Speech and HearingSciences; UNC School of MedicineRegular Lecturer, Graduate Neuropsychology Course, UNCRegular Lecturer, Undergraduate Neuropsychology Seminar, UNCNon-faculty member of Ph.D. Dissertation Committees; Suffolk University, NorthCarolina State University, University of Alabama, University of New South Wales,AustraliaMember, Neuropsychology Training Faculty; mentored clinical and researchneuropsychology fellows and interns; Brown UniversitySupervised research placements for neuropsychology pre-doctoral interns; BrownUniversityRegular lecturer for Neuropsychology Seminar Series, Brown Medical SchoolRegular lecturer for Neuropsychology Rounds, Brown Medical SchoolTraining Faculty, Neuropsychiatry/Behavioral Neurology Fellowship, Depts. OfPsychiatry & Human Behavior and, Department of Clinical Neurosciences, BrownMedical SchoolRegular lectures for Post-doctoral Fellow Lecture Series; Clinical Psychology TrainingConsortium, Brown Medical SchoolLecturer for Psychiatry Residency Training Program for PGY 1, 2, 3 and 4 LectureSeries, Brown Medical SchoolLecturer for First Year Medical Students Medical Interviewing Seminar, Brown MedicalSchoolMentor for Undergraduate Independent Study Courses, Departments of Neuroscience,Psychology, and others, Brown UniversitySupervised Practicum Training Site for Clinical Psychology Graduate Students,Undergraduate Psychology Internship Placement; URIAnnual lecturer for “Basic Neurosciences” Course, Behavioral Neurosciences Program,BUSMClinical Practicum Supervisor; Suffolk University Clinical Psychology ProgramCoordinator, Internship Training Program Neuropsychology Track, Brown UniversityClinical Psychology Training ConsortiumTraining Committee Member; Brown University Clinical Psychology TrainingConsortiumCore Faculty Member, Brown University T32 Dementia Research Training ProgramAnnual lecturer for “Human Neuropsychology Seminar,” Behavioral NeurosciencesProgram, BUSMLecturer for Neurology Residency Training Program Lecture SeriesAdvisor (for 40 graduate students), BUSM Graduate Medical Sciences Masters ProgramDirector, Post-Doctoral Neuropsychology Training Program, Alzheimer’s DiseaseCenter, BUSMDirector and Lecturer for Neuropsychology and Dementia Seminar Series, GeriatricMedicine, Dentistry & Psychiatry Fellowship ProgramConsulting Neuropsychologist and Research Mentor, APA Accredited Internship andFellowship Clinical Neuropsychology Training Program; Bedford (MA) Veterans AffairsMedical CenterCourse Co-Director, “Neuropsychological Assessment” Course, BehavioralNeurosciences Program, BUSM

CV: Robert A. Stern, 016-Present2017-Present2018-Present-Page 8Lecturer for “Biology of Disease” (Neurology) Course, BUSM Preclinical MedicalSchool CourseCME Annual Course Co-Director, Brain Trauma and the Athlete, BUSMCore Faculty Member, Alzheimer’s Disease Translational Research Training Program(National Institute on Aging T32), BUSMCME Course Co-Director, Chronic Traumatic Encephalopathy, co-sponsored by BUSMand the Cleveland Clinic Lou Ruvo Center for Brain Health; Las Vegas, September 30October 1, 2012Lecturer for “Molecules to Molecular Therapeutics” Course, Division of GraduateMedical Sciences, BUSMThesis Mentor, Physician Assistant Program, BUSMCME Course Co-Director, Chronic Traumatic Encephalopathy Conference, BostonUniversity School of Medicine, Annually held in fallLecturer for “Medical Neuroscience Module” for First Year Medical Students, BUSMLecturer for “Disease & Therapy (DRx) Curriculum” Neurology Module for SecondYear Medical Students, BUSMMAJOR MENTORING ACTIVITIES:Undergraduate Honors Theses Supervised1991Wendy Cox, “Effects of Physostigmine on Mood and Sustained Attention,” PsychologyDepartment, University of North Carolina1992Boykin Robinson, “Self-Report of Emotional and Cognitive Complaints in Individuals withGraves’ Disease: A Survey Study,” Psychology Department, University of North Carolina1996Mara Lowenstein, “Neuropsychological Functioning in Alzheimer’s Disease and VascularDementia: A Qualitative Assessment of the Rey-Osterrieth Complex Figure,” PsychologyDepartment, Brown University1997Yamini Subramanian, “The Thyroid Axis and Seizure Threshold: Examining a Mechanism ofThyroid Hormone Augmentation of ECT,” Neuroscience Department, Brown University2002Anna Podolanczuk, “Thyroid Hormone Levels in Post-Mortem Alzheimer’s and Control Brains,”Neuroscience Department, Brown UniversityMaster’s Theses Supervised1998Jennifer Latham, “The Visual Analog Mood Scales for Adolescents : A Preliminary Examinationof Reliability and Validity,” Psychology Department, University of Rhode Island2000Jessica Somerville, “A Comparison of Administration Procedures for the Rey-OsterriethComplex Figure: Flow-Charts Vs. Pen-Switching,” Psychology Department, University ofRhode Island2000Susan L. Legendre, “The Influence of Cognitive Reserve on Memory After ElectroconvulsiveTherapy,” Psychology Department, University of Rhode Island2005Veronica Santini, “Thyroid-Neurobehavioral Relationships in the Elderly,” Division of GraduateMedical Sciences, BUSM2006Daniel Daneshvar, “Association between Smoking, APOE, and Risk for Mild CognitiveImpairment and Alzheimer’s Disease,” Division of Graduate Medical Sciences, BUSM2006Laura Ridgely, “The Public Health Risk of Unsafe Elderly Drivers and Drivers with Dementia:Current Problems and Steps to be Taken,” Division of Graduate Medical Sciences, BUSM2007David Essaff, “Executive Dysfunction in Early Alzheimer's Disease (AD) and Mild CognitiveImpairment: A Potential Cognitive Marker for Preclinical AD,” Division of Graduate MedicalSciences, BUSM2007Meghan Lembeck, “Racial Disparities and Mild Cognitive Impairment Diagnosis: The Effects ofLiteracy Correction on Neuropsychological Test Scores,” Division of Graduate MedicalSciences, BUSM

CV: Robert A. Stern, Ph.D.20082009201120132016201620162019-Page 9Jessica A. Riggs, “Current Approaches to Alzheimer’s Disease Treatment: A Focus on PassiveImmunotherapy,” Division of Graduate Medical Sciences, BUSMVlada Doktor, “Clinical utility of Self and Informant’s Complaint in Mild Cognitive Impairmentand the Rate of Progression to Alzheimer’s Disease,” Division of Graduate Medical Sciences,BUSMJohn Picano, “Defining Concussions: A Literary and Empirical Analysis of Sports-RelatedConcussion,” Division of Graduate Medical Sciences, BUSMAlexandra Bourlas, “The Effects of Level and Duration of Play on Cognition, Mood and Behavioramong Former Football Players,” Division of Graduate Medical Sciences, BUSMSteven Forlivio, “The Effects of Repetitive Head Impacts on Neuroimaging and Fluid Biomarkersin College Athletes,” Division of Graduate Medical Sciences, BUSMAlyssa M. Schmitt, “Change in Body Mass Index and Neurocognitive Effects in Retired NFLPlayers,” Division of Graduate Medical Sciences, BUSMJohn Hayden, “Validating and Testing the Versatility of the Cumulative Head Impact Index”Sydney Carpenter, Characterizing a Symptom Profile in Former Athletes,” Division of GraduateMedical Sciences, BUSMDoctoral Dissertations Supervised1991Susan L. Silva, “The Effects of Physostigmine on Cognition, Mood, and Behavior,” Departmentof Psychology, North Carolina State University1993Mark L. Prohaska, “Thyroid, Lithium, and Cognition: The Use of Thyroid HormoneAugmentation in the Reduction of Cognitive Side Effects Associated with LithiumMaintenance,” Psychology Department, University of Alabama1999Debbie J. Javorsky, “A Validation Study of the Boston Qualitative Scoring System (BQSS) forthe Rey-Osterrieth Complex Figure,” Psychology Department, University of Rhode Island2003Susan L. Legendre, “The Influence of Cognitive Reserve on Neuropsychological FunctioningAfter Coronary-Artery Bypass Grafting (CABG)," Psychology Department, University of RhodeIsland2004Jessica Somerville Ruffolo, “Visuoconstructional Impairment: What Are We Assessing and HowAre We Assessing It?,” Psychology Department, University of Rhode Island2014Stacy Anderson, “Episodic Memory and Executive Function in Familial Longevity” (SecondReader), Behavioral Neurosciences Program, BUSM.2015Julie Stamm, “Later-Life Structural and Functional Consequences of Youth Exposure toRepeated Head Impacts;” Mentor for NIH F31 Grant 1F31NS081957; 2013-2015; CurrentPosition: Postdoctoral Fellow, University of Wisconsin2019Philip Montenigro (MD/PhD), “Clinical Diagnosis and Risk Factors for Chronic TraumaticEncephalopathy;” Department of Anatomy and Neurobiology, Dissertation Defended April 20162019Sean Tobyne, “Network Organization of Sensory Biased and Multi-Sensory Working Memoryand Attention in Human Cortex with fMRI,” Graduate Program in Neuroscience, BUSM (Stern,2nd Reader); Co-sponsor for NIH F31 Grant 1F31NS03306.Post-Doctoral Fellows Trained1991-1993Susan Silva, Ph.D., now Research Associate Professor at Duke University1992-1993Mareah Steketee, Ph.D., now Clinical Neuropsychologist at HRC Behavioral Health& Psychiatry, North Carolina1993-1995Mark Prohaska, Ph.D., now Director, Neuropsychology Clinic, Alabama1994-1996James Arruda, Ph.D., now Professor at University of West Florida1994-1996Garrie Thompson, Ph.D., now Clinical Neuropsychologist, Florida1996-1998Geoffrey Tremont, Ph.D., now Associate Professor at Brown University

CV: Robert A. Stern, Page 10Holly Westervelt, Ph.D., now Assistant Professor of Clinical Neurology, VanderbiltUniversity School of MedicineDebbie Javorsky, Ph.D., now Clinical Neuropsychologist at Generations GeriatricMental Health, New HampshireMichael Ropacki, Ph.D., now Director of Clinical Neuroscience Research atJanssen R&D, CaliforniaCaitlin Macaulay, Ph.D., now Clinical Neuropsychologist at Lahey Clinic, MassachusettsJennifer Duncan Davis, Ph.D., now Associate Professor at Brown UniversityRichard Temple, Ph.D., now Vice President of Clinical Operations at Core Health CareLaura Brown, Ph.D., now Clinical Instructor of Neurology at Vanderbilt UniversityMary Beth Spitznagel, Ph.D., now Assistant Professor at Kent State UniversityAngela Jefferson, Ph.D., now Professor at Vanderbilt University, andDirector of the Vanderbilt Memory & Alzheimer's CenterLee Ashendorf, Ph.D., now Clinical Neuropsychologist at Bedford VAMCBrandon Gavett, Ph.D., now Assistant Professor at Univ. of Colorado, Colorado SpringsDaniel Seichepine, Ph.D., now Lecturer of Psychology at University of New HampshireElizabeth Vassey, Ph.D., now Investigator, BU ADC, Assistant Professor of Neurology,BUSM; Clinical Neuropsychologist, Boston Center for MemoryTodd Solomon, Ph.D., now Clinical Scientist III at BracketMichael Alosco, Ph.D. (recipient of NIH F32 Grant), now Assistant Professor ofNeurology, BUSMMichael Sugarman, Ph.D.

CV: Robert A. Stern, Ph.D.-Page 11PENDING OTHER SUPPORT:NoneCURRENT OTHER SUPPORT:2019-20241R01AG062624-01, PI: Luchsinger (Site/Subaward PI: Stern), Metformin in Alzheimer'sDementia Prevention (MAP), Total Subaward Costs: 865,000.2019-2022Administrative Supplement to U01NS093334, mPIs: Stern (Contact), Cummings, Reiman,Shenton; Flortaucipir (AV1451, T807) PET Dosing, Total Costs: 1,128,061.2015-20221U01NS093334-01, mPIs: Stern (Contact), Cummings, Reiman, Shenton; ChronicTraumatic Encephalopathy: Detection, Diagnosis, Course, and Risk Factors, Total Costs: 15,859,906.2011-2020P30-AG13846, PI: N. Kowall; Clinical Core Director: Stern (through 7-2019); BostonUniversity Alzheimer’s Disease Core Center; Total Costs: 5,439,500 (2017-2020).2016-2019Lilly, Site PI: Stern, A Randomized. Double-Blind, Placebo-Controlled and Delayed-StartStudy of LY3314814 in Mild Alzheimer's Disease Dementia (The DAYBREAK Study),Total Costs: 61,479 (minimum).2014-2019Alzheimer’s Therapeutics Research Institute (University of Southern California); formercontracted through the Alzheimer’s Disease Cooperative Study (ADCS), Site PI: Stern,Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4 Study), Total Costs: 956,000.2018-2028Novartis Pharmaceuticals, Site PI: Stern, A Randomized, Double-blind, Placebo-controlled,Two Cohort Parallel Group Study to Evaluate the Efficacy of CAD106 and CNP520 inParticipants at Risk for the Onset of Clinical Symptoms of Alzheimer’s Disease (Gen 1Study).2018-2028Novartis Pharmaceuticals, Site PI: Stern, A Randomized, Double-blind, Placebo-controlled,Parallel Group Study to Evaluate the Efficacy and Safety of CNP520 in Participants at Riskfor the Onset of Clinical Symptoms of Alzheimer’s Disease (Gen 2 Study).

CV: Robert A. Stern, Ph.D.-Page 12PAST OTHER SUPPORT2013-2018U01-NS086659; PI: McKee (Stern, Co-Investigator), CTE and PosttraumaticNeurodegeneration: Neuropathology and Ex Vivo Imaging, Total Costs: 6,000,0002013-2018Eisai, Inc., Site PI: Stern, A Placebo-controlled, double-blind, parallel-group, BaysianAdaptive Randomization Design and Dose Regimen-finding study to evaluate safety,tolerability and efficacy of BAN2401 in subjects with early Alzheimer’s disease, Total Costs: 391,342.2014-2018Avid Radiopharmaceuticals, Site PI: Stern, An Open Label, Multicenter Study, Evaluatingthe Safety and Imaging Characteristics of 18F-AV-1451 in Cognitively Healthy Volunteers,Subjects with Mild Cognitive Impairments, and subjects with Alzheimer’s Disease (A05).2017-2018Janssen Research & Development, Site PI: Stern, A Phase 2b/3 Randomized, Double-blind,Placebo-Controlled, Parallel Group, Multicenter Study Investigation the Efficacy and Safetyof JNJ-54861911 in Subjects who are Asymptomatic at Risk for Developing Alzheimer’sDementia (EARLY Study).2014-2018ADCS-Toyama Chemical Partnership; Site PI: Stern, A Phase 2 multi-center, randomized,double blind, placebo-controlled, parallel group study to evaluate the efficacy and safety ofT-817MA in patients with mild to moderate Alzheimer’s Disease (US202), Total Costs: 473,346.2014-2017Avid Radiopharmaceuticals; Site PI: Stern, 18F-AV-1451-A05: An open label, multicenterstudy, evaluating the safety and imaging characteristics of 18F-AV-1451 in cognitivelyhealthy volunteers, subjects with Mild Cognitive Impairment, and subjects with Alzheimer’sdisease, Total Costs: 395,222.2015-2017DoD AZ140150, PI: Lin (Subcontract PI: Stern), Measuring Glial Metabolism inRepetitive Brain Trauma and Alzheimer's Disease. Total Costs: 1,044,630; TotalSubcontract Costs: 26,660.2010-2017D01 HP08796, PI: S. Chao; Neuropsychology Director: Stern;

2008-2015 Editorial Board Member, Archives of Clinical Neuropsychology 2010-Present Review Editor, Frontiers in Neurotrauma 2011-2016 Review Editor, Frontiers in Sports Neurology 2012-2014 Series Editor, Traumatic Brain Injury Series, Alzheimer's Research and Therapy 2016-Present Associate Editor, Journal of Alzheimer's Disease